Search

Displaying results 1351 - 1360 of 1546 in total
  1. Drug

    Lacidipine

    go.drugbank.com/drugs/DB09236
    Approved

    It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved. … Compared to other dihydropyridine calcium antagonists, lacidipine exhibits a greater antioxidant activity which may confer potentially beneficial antiatherosclerotic effects [A31540].

  2. Drug

    Vardenafil

    go.drugbank.com/drugs/DB00862
    Approved

    Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its selectivity for other PDE isoforms is lower than the one detected for tadalafil.

  3. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment

  4. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene.

  5. Drug

    Alaproclate

    go.drugbank.com/drugs/DB13233
    Experimental

    Alaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s.

  6. Drug

    ReN001

    go.drugbank.com/drugs/DB05236
    Investigational

    ReN001 a strong candidate for one of the first cell-based IND applications to be submitted to the Food and Drug Administration in the United States for consideration for the treatment of stroke in humans

  7. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard

  8. Drug

    Methacholine

    go.drugbank.com/drugs/DB06709
    Approved

    Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing … [A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M<sub>3</sub> muscarinic receptors that stimulate ASM contraction

  9. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-choleste...

  10. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or m...